На этой странице перечислены больницы направления «Радиационная онкология» (включая Immunotherapy for Cancer) в Дубай, ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.
Спросите нас о «Immunotherapy for Cancer» в Дубай, ОАЭ
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 3 аккредитованных больниц (Радиационная онкология) в Дубай, ОАЭ
Рекомендуем🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Больница занимает 1-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Kings College Hospital Dubai
Больница занимает 2-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Aster Hospital Dubai
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Радиационная онкология» указано среди её специализаций и она находится в Дубай, ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «immunotherapy for cancer» в Дубай, ОАЭ?
Выбор подходящей больницы для «immunotherapy for cancer» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Радиационная онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Immunotherapy for Cancer»
Cancer immunotherapy harnesses the body's own immune system to identify, attack, and eliminate malignant cells — representing one of the most significant paradigm shifts in oncology over the past two decades. Depending on cancer type and stage, modern immunotherapy protocols achieve durable response rates of 20–45% in previously refractory cancers, with some hematologic malignancies showing complete remission rates exceeding 80% with CAR-T cell therapy. International patients choose GAF Healthcare to access world-class oncology centers in India and the UAE, where JCI- and NABH/DHA-accredited hospitals deliver cutting-edge checkpoint inhibitor regimens, adoptive cell therapies, and bispecific antibody protocols at costs that are 40–70% lower than equivalent treatment in the United States, the United Kingdom, or Western Europe. Hospital Stay: 3–7 days per treatment cycle (outpatient infusions are common; inpatient admission required for CAR-T cell therapy and high-grade immune-related adverse events) • Total Stay in Country (Fit-to-Fly): 2–6 weeks minimum before international travel is medically cleared; CAR-T recipients typically require 4–8 weeks of local monitoring post-infusion • Success Rate: Objective response rates range from 15–45% for solid tumors with PD-1/PD-L1 checkpoint inhibitors; 70–85% complete remission rates reported for relapsed/refractory B-cell lymphoma with CAR-T (axicabtagene ciloleucel / tisagenlecleucel); outcomes are highly cancer-type and biomarker dependent
Clinical Overview
Cancer immunotherapy is a class of treatments that modulates or augments the immune system's capacity to recognize tumor-associated antigens (TAAs) and mount a sustained cytotoxic response against malignant cells. Unlike conventional chemotherapy — which exerts cytotoxic effects on all rapidly dividing cells — immunotherapy is designed to achieve tumor-selective killing while generating immunological memory capable of preventing relapse. The principal biological targets include immune checkpoint proteins (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3), tumor-infiltrating lymphocyte (TIL) pathways, and surface antigens uniquely expressed on cancer cells such as CD19, CD20, HER2, and EGFR. Understanding which pathway to target requires comprehensive molecular tumor profiling, making precision diagnostics an inseparable component of modern immunotherapy. The tumor microenvironment (TME) plays a central role in immune evasion. Malignant cells upregulate checkpoint ligands (e.g., PD-L1) that bind to inhibitory receptors on cytotoxic T lymphocytes (CTLs), effectively silencing anti-tumor immunity. Checkpoint inhibitors such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) block these interactions, restoring T-cell activation. Simultaneously, strategies such as chimeric antigen receptor T-cell (CAR-T) therapy engineer the patient's own lymphocytes ex vivo to express high-affinity receptors targeting tumor-specific antigens, achieving direct cytolytic activity independent of MHC-I presentation — a mechanism tumors frequently exploit to escape conventional immune surveillance. The current standard of care integrates immunotherapy into multimodal oncology protocols. For non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS ≥50%), first-line pembrolizumab monotherapy is now preferred over platinum-doublet chemotherapy. For metastatic melanoma, dual checkpoint blockade (nivolumab + ipilimumab) demonstrates 5-year overall survival rates of approximately 52%. Tumor mutational burden (TMB-H ≥10 mutations/megabase) and microsatellite instability-high (MSI-H) status serve as pan-tumor predictive biomarkers for checkpoint inhibitor responsiveness, as recognized by FDA tissue-agnostic approvals for pembrolizumab and dostarlimab. Treatment selection demands multidisciplinary tumor board review encompassing medical oncology, molecular pathology, radiology, and — where indicated — radiation oncology.
Who is a Candidate?
• ELIGIBILITY CRITERIA: • Patients with histologically or cytologically confirmed solid tumors or hematologic malignancies for whom immunotherapy has regulatory approval or strong Level 1 evidence (e.g., NSCLC, melanoma, bladder cancer, RCC, HCC, MSI-H colorectal cancer, triple-negative breast cancer, classical Hodgkin lymphoma, diffuse large B-cell lymphoma) • Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or large B-cell lymphoma who have failed ≥2 prior lines of systemic therapy (CAR-T eligibility) • ECOG Performance Status 0–2 (patients with PS 3–4 are generally not candidates for aggressive immunotherapy unless performance decline is directly disease-related and reversible) • Adequate organ function: serum creatinine ≤1.5× ULN, ALT/AST ≤2.5× ULN (≤5× ULN for hepatic metastases), absolute neutrophil count ≥1,500/µL, platelet count ≥75,000/µL • Confirmed biomarker status via NGS/PD-L1 IHC (TPS/CPS scoring), MSI/MMR testing, TMB quantification, and relevant fusion/mutation profiling (EGFR, ALK, KRAS G12C, BRAF V600E, RET, MET) • REQUIRED DIAGNOSTIC WORKUP (PRE-TREATMENT): • Whole-body 18F-FDG PET-CT scan for baseline disease staging and response assessment • MRI brain with gadolinium contrast (mandatory for lung, melanoma, and breast primaries) • Multiplex IHC panel: PD-L1 (22C3 or 28-8 assay), CD8+ TIL density, MMR proteins (MLH1, MSH2, MSH6, PMS2) • Comprehensive genomic profiling (CGP) via FoundationOne CDx, Guardant360, or equivalent next-generation sequencing (NGS) panel • Echocardiogram (ECHO) and 12-lead ECG (mandatory before checkpoint inhibitor initiation; cardiac toxicity monitoring) • Pulmonary function tests (PFTs/DLCO) — especially critical before anti-PD-1/PD-L1 agents in patients with pre-existing interstitial lung disease • Complete metabolic panel, LFTs, TFTs (TSH, free T4), cortisol, HbA1c, and autoimmune antibody screen (ANA, ANCA, anti-dsDNA) to establish endocrine and autoimmune baseline • Hepatitis B surface antigen, Hepatitis C antibody, and HIV serology (mandatory; HBV reactivation risk with immunotherapy) • Leukapheresis eligibility assessment (CD3/CD4/CD8 cell counts, Tregs) for CAR-T candidates • CONTRAINDICATIONS & CAUTIONS: • Active, systemic autoimmune disease requiring systemic immunosuppression (e.g., active lupus nephritis, severe Crohn's disease, myasthenia gravis) — relative contraindication for checkpoint inhibitors; risk-benefit individualization required • Prior organ transplantation (solid organ or allogeneic stem cell) — high risk of graft rejection with PD-1/PD-L1 blockade • Active interstitial lung disease or pneumonitis (grade ≥2) at baseline • Uncontrolled cardiac arrhythmias or LVEF <40% (impacts CAR-T and cytokine release syndrome [CRS] management capacity) • Pregnancy or breastfeeding (immunotherapy is teratogenic; reliable contraception mandatory during and for ≥4 months post-treatment) • Concurrent live vaccine administration (contraindicated during active checkpoint inhibitor therapy) • Patients requiring chronic high-dose systemic corticosteroids (≥10 mg/day prednisone equivalent) — attenuates immunotherapy efficacy
Treatment Options & Approaches
CHECKPOINT INHIBITOR THERAPY (ANTI-PD-1 / PD-L1 / CTLA-4): This is the most widely deployed immunotherapy modality. Monoclonal antibodies block inhibitory immune checkpoints, releasing cytotoxic T-cell brake mechanisms: • Anti-PD-1 agents: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Dostarlimab (Jemperli) • Anti-PD-L1 agents: Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Avelumab (Bavencio) • Anti-CTLA-4 agents: Ipilimumab (Yervoy), Tremelimumab (Imjudo) • Dual checkpoint blockade (nivolumab + ipilimumab): Standard of care for metastatic melanoma, MSI-H colorectal cancer, malignant pleural mesothelioma, and selected NSCLC subgroups • Novel checkpoint targets in clinical use and advanced trials: LAG-3 (relatlimab — FDA-approved in combination with nivolumab for melanoma), TIM-3, TIGIT, VISTA Administration: IV infusion every 3–6 weeks; most protocols are outpatient-based, with cycle durations of 6 months to 2 years depending on disease response and toxicity profile. CAR-T CELL THERAPY (CHIMERIC ANTIGEN RECEPTOR T-CELL): CAR-T is a personalized, living drug requiring apheresis, ex vivo genetic engineering, and lymphodepleting chemotherapy prior to infusion. Currently approved products include: • Axicabtagene ciloleucel (Yescarta) — CD19-targeting; approved for large B-cell lymphoma and follicular lymphoma • Tisagenlecleucel (Kymriah) — CD19-targeting; approved for pediatric/young adult ALL and large B-cell lymphoma • Lisocabtagene maraleucel (Breyanzi) — CD19-targeting; approved for large B-cell lymphoma and CLL • Idecabtagene vicleucel (Abecma) — BCMA-targeting; approved for relapsed/refractory multiple myeloma • Ciltacabtagene autoleucel (Carvykti) — BCMA-targeting; approved for multiple myeloma Process timeline: Leukapheresis → 2–4 weeks manufacturing → lymphodepletion (fludarabine/cyclophosphamide) → CAR-T infusion → 4–7 day inpatient monitoring for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is graded using ASTCT criteria; severe CRS (Grade ≥3) is managed with tocilizumab (IL-6 receptor blockade) and corticosteroids. BISPECIFIC T-CELL ENGAGERS (BiTEs) AND BISPECIFIC ANTIBODIES: Bispecific antibodies simultaneously bind a tumor antigen and CD3 on T cells, forming an immunological synapse that drives tumor cell lysis without prior T-cell sensitization: • Blinatumomab (Blincyto) — CD19×CD3; approved for B-cell ALL and MRD-positive ALL • Teclistamab (Tecvayli) — BCMA×CD3; approved for multiple myeloma • Elranatamab (Elrexfio), Talquetamab (Talvey) — emerging myeloma options • Mosunetuzumab (Lunsumio) — CD20×CD3; approved for follicular lymphoma These agents are administered subcutaneously or via continuous IV infusion and require step-up dosing schedules to mitigate CRS risk. CANCER VACCINES & NEOANTIGEN-BASED IMMUNOTHERAPY: • Sipuleucel-T (Provenge): Autologous dendritic cell vaccine; approved for metastatic castration-resistant prostate cancer (mCRPC) • mRNA neoantigen personalized vaccines (e.g., mRNA-4157/V940 in combination with pembrolizumab): Phase 2/3 data in melanoma show significant recurrence-free survival improvement; compassionate access available at select centers • BCG intravesical therapy: Standard immunotherapy for non-muscle-invasive bladder cancer (NMIBC), administered directly into the bladder post-TURBT CYTOKINE THERAPIES: • High-dose IL-2 (aldesleukin): Established in metastatic melanoma and renal cell carcinoma; significant toxicity profile limits use to high-volume centers with dedicated ICU support • Pegylated IL-2 (bempegaldesleukin): Improved safety profile; in combination trials with nivolumab • IL-15 superagonist (N-803): Combined with BCG for bladder cancer ANTIBODY-DRUG CONJUGATES (ADCs) WITH IMMUNOLOGIC MECHANISMS: • Enfortumab vedotin (Padcev) + pembrolizumab: First-line standard for cisplatin-ineligible advanced urothelial cancer • Sacituzumab govitecan (Trodelvy): TROP2-targeting; approved for TNBC and urothelial cancer • Trastuzumab deruxtecan (Enhertu): HER2-targeting; approved for HER2-positive breast, gastric, and HER2-low breast cancers COMBINATION CHEMOIMMUNOTHERAPY: Several FDA/EMA-approved regimens combine checkpoint inhibitors with platinum-based chemotherapy to leverage chemotherapy-induced immunogenic cell death: • Carboplatin/paclitaxel/pembrolizumab (Keynote-789 platform) for metastatic NSCLC • FOLFOX/FOLFIRI + nivolumab (CheckMate 8HW) for MSI-H/dMMR colorectal cancer • Gemcitabine/cisplatin + durvalumab (TOPAZ-1) for biliary tract cancers These regimens require full oncology infusion suite infrastructure with pharmacovigilance protocols for overlapping toxicity management.
Восстановление
PHASE 1 — PRE-TREATMENT EVALUATION (WEEKS 1–3, OFTEN COMPLETABLE REMOTELY): • Upload all existing pathology reports, imaging (PET-CT, MRI, CT), surgical/biopsy records, and prior treatment summaries to GAF Healthcare's secure patient portal for remote multidisciplinary tumor board (MDT) review • GAF Healthcare coordinates an initial teleconsultation with a board-certified medical oncologist specializing in your cancer type within 48–72 hours • Biomarker testing is arranged: if tissue blocks are available, NGS/CGP and IHC panels are initiated immediately; liquid biopsy (ctDNA) may substitute or supplement if tissue is inadequate • Baseline organ function labs, cardiac evaluation (ECHO, ECG), and autoimmune/endocrine screening are scheduled upon arrival • Medical visa (India: e-Medical Visa, processed in 3–5 business days) or UAE entry documentation is arranged by GAF Healthcare's concierge team PHASE 2 — ARRIVAL AND INSTITUTIONAL WORKUP (DAYS 1–5 IN COUNTRY): • Airport transfer arranged to partner hospital or designated patient accommodation • In-person consultation with lead oncologist and MDT; final treatment plan ratified • Any pending diagnostics completed on-site (PET-CT, MRI brain, PFTs, repeat biopsy if required) • Treatment consent, pharmacogenomic counseling, and patient/caregiver education session conducted with clinical nurse specialist and GAF Healthcare patient coordinator • For CAR-T candidates: leukapheresis performed on Day 3–5; cells shipped to manufacturing facility (2–4 week turnaround) PHASE 3 — TREATMENT INITIATION: For Checkpoint Inhibitor Therapy: • Cycle 1 IV infusion administered in the oncology day unit (pembrolizumab: 200 mg over 30 min every 3 weeks; nivolumab: 240 mg over 60 min every 2 weeks — representative examples) • Patient monitored for 1–2 hours post-infusion for acute infusion reactions • Immune-related adverse event (irAE) monitoring initiated: daily symptom log, weekly labs (LFTs, TFTs, CBC, CMP) during first cycle • Cycles 2 and beyond may be administered at a GAF Healthcare partner clinic in the patient's home country or continued at the treating institution For CAR-T Cell Therapy: • Day 0: Hospital admission for lymphodepletion chemotherapy (fludarabine 25 mg/m²/day × 3 days + cyclophosphamide 250 mg/m²/day × 3 days) • Day +1 (after washout): CAR-T cell infusion (single IV administration, typically <30 minutes) • Days +1 to +7: Mandatory inpatient monitoring in a CRS-capable unit (ICANS-trained nursing staff, tocilizumab and corticosteroids on standby) • CRS peak onset: Days 2–7 post-infusion; ASTCT Grade ≥3 managed with IL-6 blockade • ICANS (neurological toxicity) onset: Days 5–14; managed with dexamethasone • Day +14 to +28: Outpatient follow-up with daily neurological checks and CBC/CMP monitoring • Day +28 to +30: Response assessment with PET-CT; complete remission confirmed or salvage planning initiated PHASE 4 — EARLY POST-TREATMENT MONITORING (WEEKS 2–8): • Endocrine irAE surveillance: thyroid function tests every 6 weeks; cortisol stimulation test if adrenal insufficiency suspected • Pulmonary: chest CT if new respiratory symptoms develop (pneumonitis is most common Grade 3–4 irAE with anti-PD-1 agents, incidence ~3–5%) • Dermatologic, gastrointestinal (colitis), and hepatic toxicities managed per ASCO/ESMO irAE management guidelines • Remote monitoring facilitated via GAF Healthcare's telehealth coordination platform with treating oncologist FIT-TO-FLY CLEARANCE: • Checkpoint inhibitor patients: Medically cleared for international flight after completing Cycle 1–2 (typically 3–6 weeks post-treatment initiation) provided no active Grade ≥2 irAEs and stable hemodynamic status • CAR-T patients: Minimum 4–8 weeks post-infusion before international travel; neurological clearance and B-cell aplasia monitoring (IgG levels) required prior to departure • Fit-to-fly letter issued by treating oncologist; GAF Healthcare coordinates continuity-of-care documentation package for the patient's home oncologist PHASE 5 — LONG-TERM FOLLOW-UP: • Response assessment imaging (PET-CT or CT with contrast) at 8–12 weeks post-initiation • Treatment continues as per protocol: checkpoint inhibitors typically for 24–35 cycles (2 years) or until disease progression/toxicity • Ongoing remote MDT review coordinated by GAF Healthcare; option for in-person evaluation cycles at the treating institution at 3–6 month intervals
Возможные риски
Cancer immunotherapy carries a distinct and clinically significant toxicity profile that differs fundamentally from conventional chemotherapy. The most consequential category is immune-related adverse events (irAEs), which result from non-specific immune activation affecting normal tissues. Dermatologic irAEs (maculopapular rash, vitiligo, pruritus) occur in 30–40% of patients receiving anti-PD-1 agents and are usually Grade 1–2 and manageable. Endocrinopathies — including hypothyroidism (8–12% incidence), hypophysitis (up to 17% with ipilimumab), and insulin-deficient diabetes mellitus — are frequently permanent and require lifelong hormone replacement despite being otherwise well-tolerated. Immune-mediated pneumonitis (incidence 2.5–5% with anti-PD-1 monotherapy; higher with combination regimens) carries the highest risk of treatment-related mortality and mandates immediate high-dose corticosteroid therapy (methylprednisolone 1–2 mg/kg/day) upon Grade 2 detection. Immune-mediated hepatitis (AST/ALT >3× ULN) occurs in approximately 5–10% of patients on dual checkpoint blockade and may require mycophenolate mofetil or azathioprine if steroid-refractory. For CAR-T therapy, cytokine release syndrome (CRS) affects 42–93% of recipients depending on the product and disease burden; severe CRS (Grade 3–4) occurs in 2–23% and requires ICU-level management with tocilizumab and vasopressor support. Immune effector cell-associated neurotoxicity syndrome (ICANS) manifests as encephalopathy, aphasia, seizures, or cerebral edema in 20–65% of CAR-T recipients; fatal cerebral edema has been reported in <5% of cases. Late-onset irAEs may emerge months to years after checkpoint inhibitor discontinuation, underscoring the need for indefinite endocrine and organ-function surveillance. Patients with pre-existing autoimmune conditions face significantly higher irAE risk and require individualized risk stratification by an experienced clinical immunologist working alongside the treating oncologist. Hyperprogression — paradoxical accelerated tumor growth following PD-1/PD-L1 inhibition — is documented in 10–14% of patients and represents a critical phenomenon requiring early response assessment with PET-CT at 6–8 weeks. Pseudoprogression (apparent radiographic worsening due to immune cell infiltration rather than true disease progression) occurs in approximately 5–10% of responders and should be distinguished from true progression using iRECIST criteria before treatment discontinuation.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated, end-to-end medical travel coordination service that removes logistical barriers at every stage of the immunotherapy journey, allowing patients and their families to focus entirely on treatment and recovery. VISA AND ENTRY DOCUMENTATION: For India: GAF Healthcare's dedicated visa concierge team assists patients in applying for the Indian e-Medical Visa, which permits a stay of up to 60 days (extendable) and is typically approved within 3–5 business days. The application requires a formal invitation letter from the treating JCI/NABH-accredited hospital, which GAF Healthcare coordinates directly. Companion/attendant visas (e-Medical Attendant Visa) are processed simultaneously for up to two accompanying family members. For the UAE (Dubai/Abu Dhabi): Citizens of over 50 countries receive visa-on-arrival or visa-free access to the UAE for 30–90 days. Patients from countries requiring advance authorization receive dedicated visa support letters from GAF Healthcare's UAE partner hospitals, facilitating DHA (Dubai Health Authority) or DOH (Abu Dhabi Department of Health) medical treatment entry. UAE long-stay medical visas of up to 3 months can be arranged for CAR-T or extended immunotherapy protocol patients. AIRPORT AND GROUND TRANSFERS: All patients are met at arrival by a GAF Healthcare patient escort who is aware of their medical condition and any mobility or wheelchair requirements. Private, climate-controlled vehicle transfers are arranged between the airport, hospital, and accommodation for all appointments and discharge. For patients requiring medical-grade transport (supplemental oxygen, stretcher transfer), appropriate vehicles are pre-arranged in coordination with the receiving hospital. ACCOMMODATION: GAF Healthcare maintains partnerships with serviced apartments and hotels adjacent to all partner oncology centers in India (Mumbai, Delhi NCR, Chennai, Hyderabad, Bangalore) and the UAE (Dubai Healthcare City, Abu Dhabi Medical District). Accommodation options are matched to patient budget and clinical proximity requirements, with priority given to units featuring medical-grade air filtration, kitchen facilities for dietary management, and same-building or walkable access to the treatment facility. Attendant accommodation for one to two family members is arranged at all locations. MEDICAL COORDINATION AND TRANSLATION: A dedicated GAF Healthcare Patient Coordinator — fluent in the patient's language — is assigned from first contact through final discharge. Translators are available on-site at all partner hospitals for Arabic, Russian, French, Swahili, Uzbek, Kazakh, and other major source-country languages. The coordinator attends all key consultations, communicates daily updates to the patient's family in their home country, and serves as the direct liaison between the treating oncology team and GAF Healthcare's clinical oversight team. CONTINUITY OF CARE AND TELEMEDICINE: Post-departure, GAF Healthcare maintains a 12-month care coordination relationship. Full medical records, discharge summaries, imaging CDs, pathology blocks, and irAE management protocols are compiled in a structured package translated into English and the patient's preferred language for handover to their home oncologist. Scheduled telemedicine follow-up appointments with the treating oncologist are arranged at 4-week intervals for the first 6 months. Emergency clinical escalation contacts at the treating hospital are provided directly to the patient and their home physician.
Частые вопросы о процедуре «Immunotherapy for Cancer»
What is the cost of Cancer Immunotherapy in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home?
What is the success rate of Cancer Immunotherapy?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «immunotherapy for cancer» в Дубай, ОАЭ
Найдите лучшие больницы для «immunotherapy for cancer» в Дубай, ОАЭ
На этой странице представлено 3 больниц в Дубай, ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Immunotherapy for Cancer» в Дубай, ОАЭ
Сколько больниц направления «Радиационная онкология» представлено в Дубай, ОАЭ?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дубай, ОАЭ?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Immunotherapy for Cancer» в Дубай, ОАЭ.
Свяжитесь с нами, если заметите неточность на этой странице.